Trajenta DUO

Description

Indications:
Type 2 diabetes mellitus:
as monotherapy in patients with inadequate glycemic control only against the background of diet and exercise, with metformin intolerance or contraindication to its use due to renal failure;
as a two-component combination therapy with metformin, sulfonylurea derivatives or thiazolidinedione in case of failure of diet therapy, exercise and monotherapy with these drugs;
as a three-component combination therapy with metformin and sulfonylurea derivatives in case of failure of diet therapy, exercise and combination therapy with these drugs;
Active ingredient: Linagliptin & Metformin
CONTRAINDICATED in TYPE 1 DIABETES

Prescription medicine